Home > Products > Csl & CD3 > Recombinant Anti-Csl x Anti-CD3 Bispecific Antibody (Miniantibody)

Recombinant Anti-Csl x Anti-CD3 Bispecific Antibody (Miniantibody)  (CAT#: MNAB-144)

Recombinant Anti-Csl x Anti-CD3 Bispecific Antibody (Miniantibody) is a fusion protein of two scFv fragments combined with distinct specificity. One scFv of an anti-Csl antibody variable domain is linked to another scFv of an anti-CD3 antibody variable domain by a flexible hinge region. This BsAb format has the decreased size and better penetration than conventional IgGs in the clinical diagnostics and potentially therapy. This BsAb can retarget T cells to tumor cells. It is designed for the research of Breast cancer; Glioma cancaer; Glioblastoma; Multiple myeloma (MM); Leukemia therapy.
Datasheet INQUIRY

Specifications

Targets
Csl & CD3
Type
scFv-based Bispecific Fragments
Species Reactivity
Human
Application
FuncS; Promising therapeutic agent
Related Disease
Breast cancer; Glioma cancaer; Glioblastoma; Multiple myeloma (MM); Leukemia

Targets

Target 1
Csl
Gene ID
UniProt ID
Alternative Names
SUH; csl; AOS3; CBF1; KBF2; RBP-J; RBPJK; IGKJRB; RBPSUH; IGKJRB1; recombination signal binding protein for immunoglobulin kappa J region; RBPJ; Lag-1; Suppressor of hairless
Target 2
CD3
Gene ID
UniProt ID
Alternative Names
CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3
Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.
Online Inquiry

Related products of "Csl & CD3"

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-Csl x Anti-CD3 Bispecific Antibody (Miniantibody) (MNAB-144). Click the button below to contact us or submit your feedback about this product.